The median PFS of patients in group CD/CSS+SNV is significantly higher than that in group CD and group CSS (Fig 2), which indicates that different mutation subtypes of EGFR exon19 can influence the therapeutic effect of EGFR-TKIs on advanced non-small cell lung adenocarcinoma. This evidence concerns the gene EGFR and non-small cell lung adenocarcinoma.